Terms: = Ovarian cancer AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1
229 results:
1. Global, regional, and national burden of non-communicable diseases attributable to occupational asbestos exposure 1990-2019 and prediction to 2035: worsening or improving?
Miao X; Yao T; Dong C; Chen Z; Wei W; Shi Z; Xu T; Shao J; Niu Q; Rui D; Hu Y; Yan Y
BMC Public Health; 2024 Mar; 24(1):832. PubMed ID: 38500093
[TBL] [Abstract] [Full Text] [Related]
2. Racial and Ethnic Disparities in Clinical Trial Enrollment Among Women With Gynecologic cancer.
Khadraoui W; Meade CE; Backes FJ; Felix AS
JAMA Netw Open; 2023 Dec; 6(12):e2346494. PubMed ID: 38060227
[TBL] [Abstract] [Full Text] [Related]
3. Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood cancer Survivor Study and St Jude Lifetime Cohort.
Im C; Lu Z; Mostoufi-Moab S; Delaney A; Yu L; Baedke JL; Han Y; Sapkota Y; Yasui Y; Chow EJ; Howell RM; Bhatia S; Hudson MM; Ness KK; Armstrong GT; Nathan PC; Yuan Y
Lancet Oncol; 2023 Dec; 24(12):1434-1442. PubMed ID: 37972608
[TBL] [Abstract] [Full Text] [Related]
4. Effects of radiotherapy on the survival of patients with stage IA and low-grade stage IB uterine endometrioid carcinoma.
Li S; Yi Z; Li M; Zhu Z
Sci Rep; 2023 Nov; 13(1):19883. PubMed ID: 37963944
[TBL] [Abstract] [Full Text] [Related]
5. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Ledermann JA; Shapira-Frommer R; Santin AD; Lisyanskaya AS; Pignata S; Vergote I; Raspagliesi F; Sonke GS; Birrer M; Provencher DM; Sehouli J; Colombo N; González-Martín A; Oaknin A; Ottevanger PB; Rudaitis V; Kobie J; Nebozhyn M; Edmondson M; Sun Y; Cristescu R; Jelinic P; Keefe SM; Matulonis UA
Gynecol Oncol; 2023 Nov; 178():119-129. PubMed ID: 37862791
[TBL] [Abstract] [Full Text] [Related]
6. Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for ovarian cancer.
Leman R; Muller E; Legros A; Goardon N; Chentli I; Atkinson A; Tranchant A; Castera L; Krieger S; Ricou A; Boulouard F; Joly F; Boucly R; Dumont A; Basset N; Coulet F; Chevalier LM; Rouleau E; Leitner K; González-Martin A; Gargiulo P; Lück HJ; Genestie C; ; Ray-Coquard I; Pujade-Lauraine E; Vaur D
Clin Cancer Res; 2023 Nov; 29(21):4419-4429. PubMed ID: 37756555
[TBL] [Abstract] [Full Text] [Related]
7. A quality improvement project to optimize access to psychosocial care for cancer survivors who experience fear of recurrence.
Pereira L; Nguyen P; Benea A; Townsley C
J Psychosoc Oncol; 2023; 41(6):721-731. PubMed ID: 37702764
[TBL] [Abstract] [Full Text] [Related]
8. Association of pre-diagnosis specific color groups of fruit and vegetable intake with ovarian cancer survival: results from the ovarian cancer follow-up study (OOPS).
Liu YY; Gong TT; Li YZ; Xu HL; Zheng G; Liu FH; Qin X; Xiao Q; Wu QJ; Huang DH; Gao S; Zhao YH
Food Funct; 2023 Sep; 14(18):8442-8452. PubMed ID: 37622277
[No Abstract] [Full Text] [Related]
9. The relationship of lifetime history of depression on the ovarian tumor immune microenvironment.
Hathaway CA; Townsend MK; Conejo-Garcia JR; Fridley BL; Moran Segura C; Nguyen JV; Armaiz-Pena GN; Sasamoto N; Saeed-Vafa D; Terry KL; Kubzansky LD; Tworoger SS
Brain Behav Immun; 2023 Nov; 114():52-60. PubMed ID: 37557966
[TBL] [Abstract] [Full Text] [Related]
10. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.
May T; Bernardini M; Lheureux S; Aben KKH; Bandera EV; Beckmann MW; Benitez J; Berchuck A; Bjørge L; Carney ME; Cramer DW; deFazio A; Dörk T; Eccles DM; Friedlander M; García MJ; Goode EL; Hein A; Høgdall CK; Jensen A; Johnatty S; Kennedy CJ; Kiemeney LA; Kjær SK; Kupryjańczyk J; Matsuo K; McGuire V; Modugno F; Paddock LE; Pejovic T; Phelan CM; Riggan MJ; Rodriguez-Antona C; Rothstein JH; Sieh W; Song H; Terry KL; van Altena AM; Vanderstichele A; Vergote I; Thomsen LCV; Webb PM; Wentzensen N; Wilkens LR; Ziogas A; Jiang H; Tone A;
Can J Surg; 2023; 66(3):E310-E320. PubMed ID: 37369443
[TBL] [Abstract] [Full Text] [Related]
11. Knockdown of circMFN2 inhibits cell progression and glycolysis by miR-198/CUL4B pathway in ovarian cancer.
Song R; Chai T; Liu J; Chu A; Sun C; Liu Z
J Biochem Mol Toxicol; 2023 Aug; 37(8):e23383. PubMed ID: 37158446
[TBL] [Abstract] [Full Text] [Related]
12. RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in ovarian cancer.
Compadre AJ; van Biljon LN; Valentine MC; Llop-Guevara A; Graham E; Fashemi B; Herencia-Ropero A; Kotnik EN; Cooper I; Harrington SP; Kuroki LM; McCourt CK; Hagemann AR; Thaker PH; Mutch DG; Powell MA; Sun L; Mosammaparast N; Serra V; Zhao P; Lomonosova E; Khabele D; Mullen MM
Clin Cancer Res; 2023 Jul; 29(13):2466-2479. PubMed ID: 37097615
[TBL] [Abstract] [Full Text] [Related]
13. Identification of Mir-182-3p/FLI-1 Axis as a Key Signaling in Immune Response in Cervical cancer: A Comprehensive Bioinformatic Analysis.
Salmerón-Bárcenas EG; Mendoza-Catalan MA; Ramírez-Bautista ÁU; Lozano-Santos RA; Torres-Rojas FI; Ávila-López PA; Zacapala-Gómez AE
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047006
[TBL] [Abstract] [Full Text] [Related]
14. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
Senkus E; Delaloge S; Domchek SM; Conte P; Im SA; Xu B; Armstrong A; Masuda N; Fielding A; Robson M; Tung N
Int J Cancer; 2023 Aug; 153(4):803-814. PubMed ID: 36971103
[TBL] [Abstract] [Full Text] [Related]
15. Statistical Analysis of Multiplex Immunofluorescence and Immunohistochemistry Imaging Data.
Wrobel J; Harris C; Vandekar S
Methods Mol Biol; 2023; 2629():141-168. PubMed ID: 36929077
[TBL] [Abstract] [Full Text] [Related]
16. [The expression and significance of protease activated receptor 2 in ovarian epithelial carcinoma].
Liu SH; Ma YM; Zhang YN; Zhao XH; Wang HY; Li B
Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):64-73. PubMed ID: 36709122
[No Abstract] [Full Text] [Related]
17. Premature ovarian insufficiency in female adolescent and young adult survivors of non-gynecological cancers: a population-based cohort study.
Flatt SB; Baillargeon A; McClintock C; Pudwell J; Velez MP
Reprod Health; 2023 Jan; 20(1):4. PubMed ID: 36593491
[TBL] [Abstract] [Full Text] [Related]
18. Disease-free survival does not differ according to fertility preservation technique for young women with breast cancer.
Sonigo C; Amsellem N; Mayeur A; Laup L; Pistilli B; Delaloge S; Eustache F; Sifer C; Rakrouki S; Benoit A; Peigné M; Grynberg M
Fertil Steril; 2023 Mar; 119(3):465-473. PubMed ID: 36473609
[TBL] [Abstract] [Full Text] [Related]
19. Other Primary Malignancies in Patients with Breast cancer Who Undergo Germline Panel Testing.
Murphy BL; Yi M; Gutierrez Barrera AM; Tripathy D; Hunt KK; Arun BK
Ann Surg Oncol; 2023 Mar; 30(3):1663-1668. PubMed ID: 36094691
[TBL] [Abstract] [Full Text] [Related]
20. Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
van Stein RM; Engbersen MP; Stolk T; Lopez-Yurda M; Lahaye MJ; Beets-Tan RGH; Lok CAR; Sonke GS; Van Driel WJ
Gynecol Oncol; 2022 Nov; 167(2):269-276. PubMed ID: 36088169
[TBL] [Abstract] [Full Text] [Related]
[Next]
